TITLE

Transition Therapeutics: showing potential in hepatitis

PUB. DATE
September 2006
SOURCE
PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p33
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports that Toronto-based Transition Therapeutics Inc. has posted positive 12-week data from a phase I/II trial investigating the safety and efficacy of HCV-IET in hepatitis C non-responders. HCV-IET combines Transition's interferon enhancer EMZ702 with the current standard of care for hepatitis C, a combination therapy of pegylated interferon alpha and ribavirin.
ACCESSION #
22318001

 

Related Articles

  • Data Monitoring Committees in Practice. Kerr, David; McBride, Ruth; Shemanski, Lynn // Applied Clinical Trials;Mar2004, Vol. 13 Issue 3, p42 

    Provides information about data monitoring committees DMC) and clinical trials in the U.S. Role of DMC; Reference to the draft guidance published by the Food and Drug Administration for deciding the need of the DMC in clinical trials; Scenarios under which a DMC might recommend stopping a...

  • Clinical drug trials and the role of the nurse. Rath, Louise; Hitchcock, Alison; Oakley, Marion; Graham, Janet // Australian Nursing Journal;May2003, Vol. 10 Issue 10, p1CU 

    Presents an overview of how clinical drug trials are conducted in Australia. Phases of drug trials; Ethical considerations; Role of the research and clinical nurse in the trials. INSET: Common words associated with clinical drug trials.

  • ViroPharma Starts Second Phase III Trial For Camvia.  // Bioworld Week;7/9/2007, Vol. 15 Issue 28, p4 

    The article reports that Exton, Pennsylvania-based ViroPharma Inc. has started a second Phase III trial of the anti-cytomegalovirus (CMV) agent maribavir, a drug to prevent infection in patients undergoing liver transplantations. The compound, now named Camvia, will be assessed against oral...

  • CNS News Round-Up.  // PharmaWatch: CNS;Oct2007, Vol. 6 Issue 10, p2 

    The article offers news briefs related to pharmaceuticals in the U.S. Neurochem Inc. reported disappointing results from its Phase III clinical trial designed to assess the safety, efficacy and disease modification effect of Alzhamed. Transition Therapeutics Inc. stated that its experimental...

  • Alzheimer's Disease Update.  // PharmaWatch: CNS;Oct2007, Vol. 6 Issue 10, p5 

    The article offers news briefs related to Alzheimer's disease drug trial in the U.S. Neurochem Inc. has reported disappointing top-line results from its Phase III clinical trial designed to assess the safety, efficacy and disease modification effect of Alzhamed for the treatment of Alzheimer's...

  • Can Animal Models of Disease Reliably Inform Human Studies? Van der Worp, H. Bart; Howells, David W.; Sena, Emily S.; Porritt, Michelle J.; Rewell, Sarah; O'Collins, Victoria; Macleod, Malcolm R. // PLoS Clinical Trials;Mar2010, Vol. 7 Issue 3, Special section p1 

    The article discusses the feasibility of using the results of animal studies as a basis to determine the efficacy of a treatment strategy in clinical trials. It cites several reasons on why animal studies have failed to support the results in clinical trials, such as critical disparities and...

  • Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial Results Suñé, Pilar; Suñé, Josep Maria; Montoro, J. Bruno // PLoS Clinical Trials;Jan2013, Vol. 8 Issue 1, p1 

    Objectives: Publication bias may affect the validity of evidence based medical decisions. The aim of this study is to assess whether research outcomes affect the dissemination of clinical trial findings, in terms of rate, time to publication, and impact factor of journal publications. ...

  • Are randomized controlled trials controlled? Patient preferences and unblind trials. McPherson, Klim; Britton, Annie R.; Wennberg, John E. // Journal of the Royal Society of Medicine;Dec1997, Vol. 90 Issue 12, p652 

    The most reliable information about treatment effects comes from randomized controlled trials (RCTs). However, the possibility of subtle interactions—for example, between treatment preferences and treatment effects—is generally subordinated in the quest for evidence about main...

  • Precautionary Principles. Corneliussen, Filippa // European Pharmaceutical Executive;May/Jun2006, p58 

    The article focuses on need for the biopharmaceutical industry to examine the oversight framework to regulate biomedical research and development activities in the private sector and to address how these laws and regulations affecting individual companies differ depending on the specific...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics